• 沒有找到結果。

VGHTC Drug Bulletin

N/A
N/A
Protected

Academic year: 2022

Share "VGHTC Drug Bulletin "

Copied!
8
0
0

加載中.... (立即查看全文)

全文

(1)

έ̚ၷᓁᘽੈ!

VGHTC Drug Bulletin

發行人:王丹江 總編輯:陳本源 (04)23592539

編 輯:鄭鴻基、湯念湖、洪娟瑜、劉媖媚、劉兆鴻

地 址:台中市中港路三段 160 號 藥劑部 毒藥物諮詢中心 網 址:http://www3.vghtc.gov.tw:8082/pharmacy/pharmacy1.htm 電子信箱:[email protected]

創刊日期:八十三年一月二十日

Adalimumab

߸ऍ༉ ᘽर

݈֏!

Adalimumab (HumiraĂ ೇᔙ)ߏ˘჌

ԩཚሳᗼѪЯ̄(TNF- alpha)۞ಏঀԩវĂ ϡٺࢲᒅ়ّঽ۞ڼᒚĄ2002 ѐ઼࡚ࢴݡ ᄃᘽۏგநԊ(FDA)८ࣞٺᓜԖ˯ֹϡć኎

Ϡཌϫ݈८ࣞ۞ዋᑕাΒ߁Ĉᙷࢲᒅّᙯ༼

ۆă઀ᝓّᙯ༼ۆăᆉّۡਖഛۆăҹษͩ

া̈́઀ᝓĄ ᘽநүϡ!

Adalimumab ၆ٺΞ໘ّཚሳᗼѪЯ

̄ (TNF-alpha) ׍ѣ੼ޘ۞Ꮠ׶ّ׶૞˘

ّĂҭ၆(TNF-beta)݋൑ͅᑕĄAdalimumab ᖣϤܡᕝᄃp55 ׶ p75 ௟ࡪܑࢬ TNF ତצ ጡඕЪֹ҃TNF εΝ߿ّĄTNF ߏ˘჌ᄃ ϒ૱൴ۆ׶Һࠪͅᑕѣᙯ۞͇൒Ϡј௟ࡪ

፬৵ (cytokine)Ąдᙷࢲᒅّᙯ༼ۆă઀ᝓ

ّᙯ༼ۆ̈́ᆉّۡਖഛۆঽଈ۞ᙯ༼୵̚

఼૱Ξ൴ன TNF ፧ޘྵ੼Ă၆ঽநّ൴ۆ

׶ᙯ༼৔ᗼԷႊ඾ࢦࢋ۞֎ҒĄTNF ۞፧

ޘᆧΐ˵֍ٺ઀ᝓଈ۰ĂֹϡAdalimumab

ڼ ᒚ Ξ ࢫ Ҳ ܑ ϩ ۞ ݓ ޘ ׶ ൴ ۆ ௟ ࡪ ۞ ও ማĄAdalimumab ˵Ξአ༼Ϥ TNF ᄵ൴ٕ

ଠט۞ϠۏͅᑕĂΒ߁࢑యϨҕ஧௟ࡪொજ

۞ᕆ඾̶̄፧ޘ۞ԼតĄ

ᙷ ࢲ ᒅ ّ ᙯ ༼ ۆ ঽ ଈ д ତ צ Adalimumab ڼᒚޢĂΞ൴னۆাާّഇͅ

ᑕۏּт C ͅᑕకϨĞCRPğĂࡓҕ஧Օ ࢫిத (ESR) ׶ҕ୻௟ࡪ፬৵ IL-6 ۞፧

ޘ ԣ ి ࢫ Ҳ Ą ٺ ҹ ษ ͩ া ঽ ଈ ˵ ൴ ன ׎ CRP ፧ޘԣి˭ࢫĄΩγĂயϠ௡ᖐГౄ

҃ ౄ ј హ ੻ ৔ ᗼ ۞ ௟ ࡪ ૄ ኳ క Ϩ ᅔ ৵ (Matrix metalloproteinases, MMP-1 ׶ MMP-3) ۞ ҕ ୻ ፧ ޘ ˵ д Ը ᄃ Adalimumab ޢࢫҲĄᙷࢲᒅّᙯ༼ۆă઀

ᝓّᙯ༼ۆ̈́ᆉّۡਖഛۆ۞ঽଈ૱൴Ϡ ᅅҌ̚ޘ۞ళҕ׶୽͐஧ᇴࢫҲĂ֭ͷົѣ

๝ّ̚Ϩҕ஧׶ҕ̈ڕᇴณ̿੼۞ன෪Ăགྷ Adalimumab ڼᒚޢ఼૱Ξ࠻ז఺ֱၙّ

ۆা۞ҕ୵޽ᇾ଀זԼචĄ າ ᘽ ̬ ௜

2 z e i n m

第 四 期

(2)

第十四卷 第四期 台中榮總藥訊 2

ᘽۏજ˧ጯ!

Adalimumab ۞ϠវΞϡதࡗ 64%Ă֗

វ̶̰Ҷវ᎕ࡗ 4.7Ƃ6.0 ̳̿Ăᙯ༼୵̰

۞፧ޘࡗࠎҕ୻̚۞ 31Ƃ96ƫĂπӮଵੵ

Η਽ഇ̂ࡗࠎ2 ฉĞଂ 10 ז 20 ͇ğĄ

጗ณᄃϡڱ!

1. јѐᙷࢲᒅّᙯ༼ۆă઀ᝓّᙯ༼

ۆٕᆉّۡਖഛۆঽଈĈޙᛉ጗ณ ࠎ Տ ׌ ฉ ϩ ˭ ڦ ड ಏ ˘ ጗ ณ 40 mgĄ׎΁็௚Լචঽଐ۞ԩࢲᒅঽ ᘽۏΞٺ Adalimumab ڼᒚഇมᚶ ᜈֹϡĄ

2. ҹษͩাĈޙᛉ጗ณࠎ౵ܐௐ˘͇

ϩ˭ڦड160 mg (Ξٺ˘͇̰ڦड Ԇ ல ٕ ా ᜈ ˟ ͇ Տ ͇ ڦ ड 80 mg)Ăତ඾ 2 ฉޢ(ௐ 15 ͇)ڦड 80 mg ĄГ࿅ 2 ฉ (ௐ 29 ͇) ฟؕՏ

׌ฉ˘Ѩග̟ჯ޺጗ณ40 mgĄͪ

໅ᅕᙷᘽۏăᙷ׽ዔ׶/ٕҺࠪአ༼

጗ ( т 6-mercaptopurine ׶ azathioprine) Ξٺڼᒚഇมᚶᜈ

ֹϡĄ

3. ઀ᝓĈܐؕ጗ณࠎ 80 mg ϩ˭ڦ डâฉ̝ޢฟؕՏ˟ฉڦड 40 mgĄ

4. ڦडొҜΒ߁̂ჿٕཛొĂޙᛉঽ ˠᑕ዇߹Հೱ߉χᘽۏ۞ొҜĄ 5. ඗၆̙Ξٺ࿅ୂă༌ܦă൴ࡓٕត

ർ۞ϩቲڦडᘽۏĄ

͹ࢋઘүϡ!

૱֍ઘүϡࠎڦडొҜͅᑕ (ূ൭ăཚ ණă൴ࡓٕສᚧ)ă˯ײӛ྽ຏߖăϩቲࡓ

ৃăສᚧăি౻ăᐝ൭ă੼ҕᑅă⪰͕ăཛ ൭ăݜမăᆄݟ൭ăᆄ·ҕăᙯ༼ۆă˵ѣ

Ξਕֹք᝙ᅔ৵ᆧΐඈĄ ڦຍְี!

1. അ၆ adalimumab ൴Ϡ࿅ୂͅᑕ ۰Ă̙ΞͽֹϡĄ

2. ϡᘽഇมᔖҺ߉χࠪࡺĄ

3. ֶፂઉܲఢؠĂืଵੵֹϡ۞ࢦࢋ

ېڶΒ߁Ĉ

(1)ᘃθٕϒд଱֯۞૎̃

(2)߿જّຏߖা̝ঽଈ

(3)׍੼ޘຏߖ፟ົ۞ঽଈĂΒ߁Ĉ 1ၙّჿొሚႹ̝ঽଈ2А݈അ ଈѣඕ८ঽ (А݈അଈѣ TB ۞ଈ ۰Ăтڍ̏གྷତצ࿅Ԇፋᒚ඀۞ԩ ඕ८ᘽۏڼᒚĂ̪ΞତצڼᒚĂҭ ᑕซҖྎ௟۞ෞҤĂͽҺඕ८ঽГ ޘೇ൴ć҃дฟؕڼᒚ̝݈ĂϺᑕ

҂ᇋଈ۰۞Пᐍ/ड़ৈͧ)3࿅Ν 12 ̰࣎͡അѣຏߖّᙯ༼ۆ۰4 ѣˠ̍ᙯ༼ຏߖĂࡶྍˠ̍ᙯ༼Ϗ

ੵΝ݈Ă̙Ξֹϡ5࿱׽ّٕೇ൴

ّ۞਒ටຏߖা6׍ѣ঻ཉጱԌ გ۰

(4)ೋّཚሳٕᒛ݈ېၗ̝ঽଈ (ҭ

̙Β߁̏གྷତצ࿅·̶ڼᒚ྿ 10 ѐͽ˯۞ೋّཚሳ)

(5)к൴ّർ̼া(multiple sclerosis) 4. тڍ൴Ϡ˭Еன෪ᑕઃͤڼᒚĈ

(1)ᒚड़̙ၓ

(2)̙։ְІĂΒ߁Ĉ1ೋّཚሳ2 ྍ ᘽ ۏ ͔ ੓ ۞ ᚑ ࢦ ߲ ّ 3 ᘃ θ (ᇶॡઃᘽӈΞ) 4 ᚑࢦ۞ม൴ّ

ຏߖা (ᇶॡઃᘽӈΞ)

(3)

ᄃ Etanercept ۞ͧྵ

EtanerceptĞEnbrelĂा౾ğ ࠎ˘ᗕ

̶̄۞p75 ཚሳᗼѪЯ̄ତצវᙷҬۏĂΞ ͽТॡᄃཚሳᗼѪЯ̄TNF-α ׶ TNF-β ඕ ЪĂ҃Ժטវ̰ཚሳᗼѪЯ̄۞߿ّĂᖣͽ Լච൴ۆېၗ̈́ҺࠪͅᑕĄᄃAdalimumab

ౌߏᛳٺϠۏᄦ጗Ăүϡ፟ᖼ̙Тٺ็௚۞

ԩࢲᒅঽᘽۏĂᓜԖ˯ᘽड़யϠ۞ॡมࡗд ϡᘽޢᇴ͇Ҍˬ̰࣎͡Ąֹϡ͞ёߏϩ˭ڦ ड˘ฉ׌ѨâѨ25 mgĄ׌۰̝ͧྵтܢ

ܑĄ

Adalimumab ᄃ Etanercept ̝ͧྵ!

ጯ Щ Adalimumab Etanercept

થ ݡ Щ Humira Enbrel

ј̶ӣณ 40 mg/0.8 ml (pre-filled synringe) 25 mg /vial

኎Ϡཌ८ࣞዋᑕা ᙷࢲᒅّᙯ༼ۆă઀ᝓّᙯ༼ۆă ᆉّۡਖഛۆăҹษͩা̈́઀ᝓ

ᙷࢲᒅّᙯ༼ۆă઀ᝓّᙯ༼ۆă ᆉّۡਖഛۆăρѐݭᙷࢲᒅّᙯ

༼ۆ

үϡ፟ᖼ ԩTNF alpha ಏঀԩវ Ξ໘ّTNF ତצវᙷҬۏ ଵੵΗ਽ഇ (t 1/2) 10~20 ͇ 4~5 ͇

ฟؕүϡॡม(onset) 1~2 ฉ 1~4 ฉ

ϡڱ ϩ˭ڦडĂՏ׌ฉ˘Ѩ ϩ˭ڦडâฉ׌Ѩ

׊ආ጗ณ (ֶវࢦࢍზ)

15~30 kg: 20 mg Q2W

>30 kg: 40 mg Q2W

0.4 mg/kg, up to 25 mg twice weekly

ᘃθщБ৺ᇴ B B

ઉܲఢؠ ׌۰࠰ืགྷְ݈ᆶߤ८ࣞޢֹϡ

ᘽݡಏᆊĞ̮ğ 17784 4275

Ηѐᒚ඀ᘽ෱Ğ̮ğ 213,408 205,200

ᄦౄᘽᇄ Abbott Wyeth / Amgen

ણ҂ྤफ़Ĉ!

1. Micromedex® Healthcare SeriesĂ2007 2. ᘽݡϼಏ

3. ઉܲග;ఢؠ!

(4)

第十四卷 第四期 台中榮總藥訊 4

ᔖҺ Ceftriaxone ᐖਔڦड጗ᄃӣถ໘୵׀ϡ!

ᆒ媖಩ ᘽर

2007 ѐ 9 ઼࡚͡ࢴݡᄃᘽۏგநԊ ĞFDA ğ ၆ ᗁ ᒚ ૞ ຽ ˠ ࣶ ൴ ΍ ˘ ݋ ᙯ ٺ ceftriaxone ڦड጗ᘽݡϼಏՀາᛋᄬ۞ੈ

िĂ͹Яߏᘲͩᘽᇄ(Roche)Ш FDA ೩΍ಡ ӘĂҋ1984 ѐ ceftriaxoneĞRocephinğ˯

ξͽֽĂ̏൴Ϡ̣࣎າϠ׊࡭Ѫ९ּć఺Ξ ਕᄃ ceftriaxone ׶ӣถ໘୵׀ϡଂᐖਔڦ डගᘽѣᙯĄ

ॲፂಡӘĂ఺ֱ࡭Ѫ९ּ࠰ࠎࡎ൒൴ Ϡć׎̚ѣαּ۞ ceftriaxone ׶ӣถ໘୵ ߏ ଂ ࠹ Т ۞ Ꮾ ڦ გ Т ॡ ග ᘽ ć Ω ˘ ּ ۞ ceftriaxone ׶ཬ෈Ꭴถڦड୵ߏଂ̙Т۞

Ꮾڦგͷٺ̙ТॡมගᘽĞৌϒ۞ॡมम֭

Ϗ೩̈́ğĄϤ׌࣎࡭Ѫ९ּྋ࣠൴னĂдາ Ϡ׊۞ඪ᝙ᄃ۱᝙ҕგѣඕ೿ᇹ۞ۏኳх дćௐˬ࣎९ּ݋൴னдᏮڦგྮ˯ѣՕ፥

ۏхдĂ҃ͷѩາϠ׊дତצ఺Օ፥ۏኳڦ डޢ̙˳Ѫ˸Ąѩ჌ᚑࢦ̙։ͅᑕߏӎົ൴

Ϡ ٺ ј ѐ ˠ ֭ ̙ ୻ ຾ ć ҭ ॲ ፂ ͛ ᚥ ceftriaxone ׶ӣถ໘୵ߏᛳٺۏநّ̙࠹

टĂົயϠՕ፥ۏćநኢ˯఺჌ࢲᐍ૟хд ٺЇңѐ᛬ᆸ۞ঽˠĄ

Яѩ FDA ఼ۢᗁᒚˠࣶĈ̙ኢϡٺң

჌ѐ᛬ᆸঽˠĂceftriaxone ̙Ξͽ׶ᐖਔڦ ड۞ӣถᘽݡ໘୵஄Ъٕ׀ϡĂ҃ͷ̙Ξͽ

ଂ࠹Т۞Ꮾڦგٕ̙Т۞ᏮڦგٕొҜග ᘽĄࡶڼᒚ˯ᅮࢋĂυืٺֹϡceftriaxone

̝ޢ48 ̈ॡĂ̖ΞͽГගӣถ໘୵ĄΩγĂ ࠎϡᘽщБԧࣇ˵ፋந΍ώੰ۞ӣถڦड ᘽ ݡ ᄃ ቢ ˯ ׌ ჌ ceftriaxone ᘽ ݡ ĞRocephin ᄃ SintrixğĂ૟ιٸдWEB ᗁ ឤ ր ௚ Ă ༊ ᗁ र Т ॡ ฟ ΍ ถ ڦ ड ᘽ ݡ ᄃ ceftriaxone ॡĂົពϯࡓҒᛋᄬĂ೩ᏹᗁर

׌۰̙Ξͽ׀ϡćԓ୕ਕࠎঽˠ۞ϡᘽщБ ԯᙯĄ

ણ҂͛ᚥĈ

1. September11, 2007-Healthcare Professional Sheet - FDA, http://www.fda.gov/medwatch/safety/2007/Rocephin 2. August 2007 - Prescribing Information – Roche ϡ ᘽ щ Б !

(5)

96 ѐ 7-9 ͡າ˯ቢᘽݡ!

ᆒЏᕃ ᘽर

ีѨ ˯ቢ͟ഇ າᘽᘽЩ ᄦౄᇄ ᘽቅ ઉܲᆊ ᄲځ

1 96.07.20

Elmiron cap 100mg (Pentosan

polysulfate sodium)

IVAX BP080 48.60 ዋᑕাĈЯมኳّ჻਋ۆ͔੓

۞჻਋ূ൭ٕ̙ዋ۞ྋੵĄ

2 96.08.22 Octide inj 0.1mg

(Octreotide) ѶϠ AO230 440.00

ዋᑕাĈ၆͘ఙăٸडቢᒚڱ

ٕDOPAMINE үϡ጗ᒚڱଠ ט൑ड़۞۳ბ۲̂াଈ۰ĂΞ ଠט׎াېĂ֭ഴ͌Ϡܜ፬৵

̈́SOMATOMEDćN-C ۞ҕ ልࣃćྋੵᄃࡤབ਍᝙̶̰ک ཚሳѣᙯ۞াېć࿰֨਍᝙͘

ఙޢ۞׀൴াĂڼᒚࡤăࢴ྽

ᐖਔѡૺ΍ҕ̈́࿰֨Г΍ҕĄ

3 96.08.22 Trileptal 6% 100ml

(Oxcarbazepine) Ꮪර AO220 568.00

ዋᑕাĈјˠԊొឩ⿔൴ү̝

ಏ˘ٕᅃӄڼᒚĂ̂ٺ˘࣎͡

ޅආឩ⿔Ԋొ൴ү̝ᅃӄڼ ᒚĄ

4 96.08.22 Pitamycin inj 2GM

(Piperacillin) ϖܫ DP170 110.00

ዋᑕাĈࢭᜋͩౚّă̈́ࢭᜋ

ͩวّနউෂ̈́ᅮউෂ͔ٙ

੓̝Б֗̈́Ԋొّຏߖ Ą

5 96.09.05 Megest susp 120ml

(Megestrol) ợᇇ BM080 1,766.00

ዋᑕাĈޢ͇Һࠪ৿ͻা࣏ཏ ଈ۰۞နࢴাăೋঽវኳٕࣧ

Я̙ځ۞វࢦځពഴᅅĄ

6 96.09.05 Lactul syr. 500 ml

(Lactulose ) Ճዂ AL660 443.00

ዋᑕাĈଈঽഇၙّܮ৪ăܝ րքཝঽតăքڃਜ਼݈ഇăք ڃਜ਼

ᘽ ݡ ள જ !

(6)

第十四卷 第四期 台中榮總藥訊 8

ีѨ ˯ቢ͟ഇ າᘽᘽЩ ᄦౄᇄ ᘽቅ ઉܲᆊ ᄲځ

7 96.09.05 Pediacel vaccine

(̣Ъ˘ࠪࡺ) ᔈᏚහ BP090 ҋ෱

1220

ዋᑕাĈΞֹ΍Ϡޢ˟࣎͡Ҍ

˛໐۞ޅආ၆Ϩಘă৔๋ࢲă Ѻ͟ݜă̈׊౫༑া̈́ܬ᝚ّ

b ݭ߹Җّຏ݂๝ҕ୛ෂຏߖ

াயϠҺࠪ˧Ą

8 96.09.12

Fosamax plus tab-70

(Alendronate 70mg +VIT.D3 2800 IU)

MSD BA510 262.00

ዋᑕাĈઃགྷ૎̃੻ኳழᗫা

̝ڼᒚĂշّ੻ኳழᗫা̝ڼ ᒚĄ

9 96.09.12 Butenafine crm 5g

(Butenafine) Ճዂ AB770 64.00

ዋᑕাĈ޽ĞశğมឣෂঽĞࢶ പཙğă๪ᝓĞវᝓğă۵ᝓ

ඈϩቲৌෂᛳឣෂ͔੓̝ϩ ቲຏߖাĄ

10 96.09.12

Fe-lib inj 2%, 5ml (Iron sucrose 400 mg= Fe+3 100 mg)

Аซ઼ᅫ AF770 97.00 ዋᑕাĈާăၙّεҕăళҕă

͘ఙޢᜠኳ৿ͻাĄ

11 96.09.14 Humira inj 40 mg

(Adalimumab) ֲૈ BA530 17,784.00

ዋᑕাĈ

1. ᙷࢲᒅّᙯ༼ۆĈHumira ዋϡٺଈѣ̚ޘҌࢦޘᙷ ࢲᒅّᙯ༼ۆ֭ͷഅགྷ၆

˘ ჌ ٕ ෹ ࿅ ˘ ჌ ۞ DMARDs ᘽۏѣ̙ዋ༊

ͅᑕ۞јˠঽଈĂΞഴᅅ

াېᄃᇈЏ(Β߁͹ࢋᓜ Ԗͅᑕ׶ᓜԖቤྋ)ăԺט ඕ ၹ ˯ ຫ च ۞ ೋ ̼ Ą Humira Ξಏ፾ֹϡ˵Ξ ͽ ׶ MTX ٕ ׎ ΁ DMARDs ᘽۏ׀ϡĄ 2. .઀ᝓّᙯ༼ۆĈዋϡٺ၆

়ঽቤྋݭԩࢲᒅᘽۏ൑

ᒚड़̝јˠ߿જّᄃซҖ

ّ઀ᝓّᙯ༼ۆĄHumira Ξಏ፾ֹϡ˵Ξͽ׶MTX

ٕDMARDs ᘽۏ׀ϡĄ 6

(7)

3. ᆉّۡਖഛۆĈዋϡٺഴ ᅅଈѣ߿જّᆉّۡਖഛ ۆ۞ঽଈ̝াېᄃᇈЏĄ 4. ҹษͩাĈዋϡٺ၆็௚

ڼᒚ൑ड़̝јˠ̚ޘҌࢦ ޘҹษͩা(CD)ĂΞഴᅅ

াېᄃᇈЏ̈́ᄵጱᄃჯ޺

ᓜԖቤྋĄHumira Ϻዋϡ ٺ၆ infliximab ̏གྷεΝ ᒚड़ٕ൑࡝צّ̝јˠ̚

ޘҌࢦޘҹษͩাĂΞഴ ᅅাېᄃᇈЏ̈́ᄵጱᄃჯ

޺ᓜԖቤྋĄ

5. ઀ ᝓ Ĉ ၆ ׎ ΁ Б ֗ ّ ڼ ᒚĂΒ߁ cyclosporineă methotrexate ٕ׎΁Ѝ̼

ጯᒚڱ൑ड़ăѣ༰ԟٕ൑

ڱ࡝צ̝̚ޘҌࢦޘ઀ᝓ

јˠଈ۰Ą 12 96.09.19 Royalsense gel 1%

(Clindamycin) Ճዂ BC400 45.20 ዋᑕাĈವ૱ّ⑉ስ

13 96.09.19

Colimycin inj 66.8 mg/2MU (Colistimethate sodium.)

ڌ߶ BC380 ҋ෱ 500

ዋᑕাĈქᓘෂă̂བෂă۱ ۆ୛ෂă֔൬ෂă̂བ୛ෂຏ ߖা Ą

14 96.09.19

Flucytosine tab 500 mg (Flucytosine)

ڌ߶ DA100 83.00 ዋᑕাĈϨҒឣෂঽăឣෂّ

۱ۆ̈́யҒឣෂঽĄ

(8)

第十四卷 第四期 台中榮總藥訊 8

ĶБϔઉ૵ܲᐍᘽݡග;ఢؠķ࣒ϒఢؠ!

10 ౢ ԩ຋Ϡۏ጗ Antimicrobial agents

)ҋ96 ѐ 9 ͡ 1 ͟੓߉Җ*

ᆒ媖಩ ᘽर

൴͛͟ഇĈ96.08.14 ઉܲᘽфௐ 0960000249 ཱི

࣒ϒޢග;ఢؠ ࣧග;ఢؠ

10.8. ׎΁ Miscellaneous

10.8.2. fluoroquinolone ᙷĈĞ96/ 9/1ğ ࢨֹϡٺ˭Е়ঽĂࡶֹϡٺඕ८ঽ̙

̟ග;Ą

10.8.2.1. moxifloxacin ˾ڇ጗ݭ(т Avelox film-coated tablet)Ĉ(91/2/1ă92/11/1ă

94/3/1)

1.ࢨϡٺјˠ(Ȉˣ໐ͽ˯)̝ၙّ͚ঈგ ۆ۞ާّೋ̼ٕۤડّ۱ۆĄ

2.Տ͟ࢨֹϡ˘௕(400mg)Ăֹϡഇมͽ̙

෹࿅Ȉ͇ࠎࣧ݋Ą

10.8.2.2.gemifloxacin ˾ڇ጗ݭ(т Factive Tablets 320mg)Ĉ(96/6/1)

1.ࢨϡٺјˠ(Ȉˣ໐ͽ˯)̝ၙّ͚ঈგ ۆ۞ާّೋ̼ٕۤડّ۱ۆĄ

2.Տ͟ࢨֹϡ˘௕Ăֹϡഇมͽ̙෹࿅˛͇

ࠎࣧ݋Ą

10.8. ׎΁ Miscellaneous 10.8.2. ाⓇᙷ quinolone

10.8.2.1. moxifloxacin ˾ڇ጗ݭ(т Avelox film-coated tablet)Ĉ(91/2/1ă

92/11/1ă94/3/1)

1.ࢨϡٺјˠ(Ȉˣ໐ͽ˯)̝ၙّ͚ঈგ ۆ۞ާّೋ̼ٕۤડّ۱ۆĄ

2.Տ͟ࢨֹϡ˘௕(400mg)Ăֹϡഇมͽ̙

෹࿅Ȉ͇ࠎࣧ݋Ą

10.8.2.2. gemifloxacin ˾ڇ጗ݭ(т Factive Tablets 320mg)Ĉ(96/6/1) 1.ࢨϡٺјˠ(Ȉˣ໐ͽ˯)̝ၙّ͚ঈგ

ۆ۞ާّೋ̼ٕۤડّ۱ۆĄ

2.Տ͟ࢨֹϡ˘௕Ăֹϡഇมͽ̙෹࿅˛͇

ࠎࣧ݋Ą

౯ොĈထቢొЊࠎາ࣒ࢎ̝ఢؠĄ ঐ ि ಡ ጱ !

參考文獻

相關文件

Special organizations currently include Macao Post (Direcção dos Serviços de Correios), Macao Postal Savings (Caixa Económica Postal), Pension Fund (Fundo de Pensões),

In the first quarter of 2014, visitor arrivals increased by 8.7%; total spending of visitors grew by 10.1%; exports of gaming services rose by 13.0% in real terms; guests of hotels

For the whole year of 2013, value added of the above-scale industries rose by 9.7% year-on-year, down by 0.3 percentage points from the increase a year earlier; fixed asset

The expansion was mainly spurred by the increase in private consumption expenditure and fixed investment, contributing 1.5 and 1.0 percentage points to economic growth; government

in building construction, soaring housing prices led to a substantial increase in property transfer fees and real estate developers’ margin, causing construction investment by

Gross Domestic Product (GDP) for the first quarter of 2012 expanded by 2.0% year-on-year and 1.9% quarter-to-quarter; the increment was driven by private consumption

The expansion was mainly spurred by the increase in private consumption expenditure, contributing 2.1 percentage points to the economic growth; fixed investment

Special organizations currently include Macao Post (Direcção dos Serviços de Correios), Macao Postal Savings (Caixa Económica Postal), Pension Fund (Fundo de Pensões),